Senolytics are compounds meant to clear senescent cells, the worn-out cells that stop dividing but do not die off, building up in aging tissue where they leak inflammatory signals. In mice the results are strong: clearing these cells kept several organs healthier and, in normally aged animals, extended median lifespan. In people the work is two small pilots so far, one in 14 patients with pulmonary fibrosis and one in 9 with diabetic kidney disease, both measuring cellular markers and physical function, neither measuring survival.
The agents span a wide range, from dasatinib, a prescription cancer drug, to fisetin and quercetin, flavonoids sold as ordinary supplements. No senolytic has been shown to extend human life or prevent an age-related disease.
Findings & Outcomes
What It Is
Senolytics are compounds that clear senescent cells, sometimes called zombie cells. A senescent cell has stopped dividing but does not die off, so it stays in the tissue and accumulates with age. It secretes a mix of inflammatory molecules called the senescence-associated secretory phenotype, or SASP, which disturbs the healthy tissue around it and adds to the low, steady inflammation of aging. Senolytics clear those cells selectively and leave healthier tissue in their place.
Senescent Cells and How Senolytics Target Them
1Cells stop dividing but do not die off
With age and stress, some cells enter senescence. They stop dividing, switch on survival programs that block the usual self-destruct signal, and remain in the tissue instead of being cleared away.
2They leak the SASP
These lingering cells secrete a mix of inflammatory signals, the senescence-associated secretory phenotype, or SASP. In this way a small number of non-dividing cells can irritate neighboring healthy tissue and sustain a low, steady background of inflammation.
3Senolytics trigger senescent-cell death
Senolytic compounds block the survival programs that senescent cells depend on, so those cells undergo the programmed death they were being kept from. The aim is to remove them while leaving healthy dividing cells largely alone.
What the Research Shows
The findings below are ordered by how strong the evidence is and how directly it applies to people, and they divide at the line between mouse and human.
The mouse work sits at the top because it shows cause, not just association. The most convincing of those studies used a genetic on-switch to delete senescent cells, not a senolytic drug, which is what lets them show that senescent cells drive aging changes instead of merely accompanying them. The drug studies came next, testing dasatinib plus quercetin, fisetin, and navitoclax against the same measures of function, tissue health, and lifespan.
The human evidence sits in a lower tier of its own: two small, open-label pilots with no control group, one in idiopathic pulmonary fibrosis and one in diabetic kidney disease, each measuring cellular markers and short physical-function tests over days to weeks. The distance between the animal work and this early human work is wide.
Strong, causal data in mice; two small, uncontrolled pilots in people, and no senolytic yet shown to extend human life or prevent an age-related disease.
One caution applies across the human tier. Both pilots, and the review most often cited to frame the field, come largely from one research group at the Mayo Clinic, some of whose members hold patents or financial interests in senolytic drugs. That does not make the results wrong, and it is a standing reason to want independent replication before firm conclusions are drawn.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
How it works
Senescent cells leak inflammatory SASP signals that harm nearby tissue
Worn-out cells that do not clear out leak inflammatory signals that irritate the healthy tissue around them.
Senescent cells that linger in tissue secrete a mix of inflammatory cytokines, chemokines, growth factors and proteases, defined as the senescence-associated secretory phenotype (SASP). This secretion lets a small number of non-dividing cells disturb surrounding healthy tissue and sustain low-grade inflammation. The SASP is well characterized in cell and tissue studies; how much of any one person's age-related decline it drives, versus the other aging processes, is harder to isolate.
The study · 1
Coppé 2008, PLoS Biology · PLoS Biology, 2008
Senolytics switch off the survival programs senescent cells rely on
Senescent cells stay alive by switching on survival programs; senolytics switch those off so the worn-out cells self-destruct.
Senescent cells survive by turning up anti-apoptotic (pro-survival) networks. Mapping those networks identified dasatinib and quercetin as the first senolytics, compounds that block the survival signals so senescent cells undergo the programmed death they had been resisting, while dividing cells are largely spared. The selectivity is partial and differs by cell type: no single compound removes only senescent cells cleanly, and the best drug targets are still being defined.
The study · 1
Zhu 2015, Aging Cell · Aging Cell, 2015
Navitoclax blocks BCL-2 survival proteins and cleared senescent cells in mice
Navitoclax blocks a survival protein senescent cells depend on, which cleared them and refreshed aged stem cells in mice.
Navitoclax (ABT263) inhibits the BCL-2 and BCL-xL survival proteins that senescent cells rely on. In aged and irradiated mice it cleared senescent cells and rejuvenated aged blood-forming and muscle stem cells. BCL-xL is also needed by platelets, so this on-target action lowers platelet counts, a dose-limiting effect that has shaped how the drug is tested.
The study · 1
Chang 2016, Nature Medicine · Nature Medicine, 2016
A three-day course cut senescent-cell counts in nine people with diabetic kidney disease
A short senolytic course measurably reduced the count of worn-out cells in human tissue, the first direct proof the drugs clear senescent cells in people.
In an open-label pilot in people with diabetic kidney disease, three days of dasatinib plus quercetin reduced the number of senescent cells in fat and skin biopsies and lowered several circulating SASP inflammatory factors when measured 11 days later. Only nine participants completed it, there was no control group, and it measured cell counts, not kidney function or any health outcome.
The study · 1
Hickson 2019, EBioMedicine · EBioMedicine, 2019
Longevity And Mortality
Clearing senescent cells delayed fat, muscle and eye aging in mice
Clearing senescent cells kept aging mice healthier for longer, delaying loss of muscle and fat tissue and the onset of cataracts.
In genetically engineered mice, switching on the removal of p16-positive senescent cells delayed the onset of age-related changes in fat, skeletal muscle and the eye, and slowed progression of disorders already under way. This used a genetic on-switch to delete the cells, not a senolytic drug, so it proves that senescent cells drive these disorders; it does not show that any pill does.
The study · 1
Baker 2011, Nature · Nature, 2011
Clearing senescent cells extended median lifespan in aged mice
Removing senescent cells let ordinary aged mice live meaningfully longer and kept several organs working better.
Clearing p16-positive senescent cells from normally aged mice extended median lifespan across two genetic backgrounds and delayed age-related deterioration of the kidney, heart and fat, without a rise in late-life illness. The clearance was again genetic, not a drug, and mouse lifespan results have often failed to carry over to people; this is a strong animal signal, not a human one.
The study · 1
Baker 2016, Nature · Nature, 2016
Fisetin lowered senescence markers and extended lifespan in aged mice
Fisetin, a plant compound, lowered senescent-cell markers and lengthened life in aged mice.
Fisetin, a flavonoid found in strawberries and other plants, reduced senescence markers in several tissues of aged mice and extended median and maximum lifespan even when started late in life. The doses were high relative to what diet provides, the work is in mice, and a supplement bought at nutritional doses is not the same as the intervention that was tested.
The study · 1
Yousefzadeh 2018, EBioMedicine · EBioMedicine, 2018
No human trial has yet shown senolytics extend life or prevent disease
In people, senolytics have moved cellular markers and small function tests so far, and no study has shown they make anyone live longer or get sick less.
Across the field, senolytic human trials remain early-phase and small, and have measured biomarkers such as senescent-cell counts and physical-function tests, not survival, disease-free years, or other hard outcomes. No trial has yet shown that senolytics extend human life or prevent an age-related disease. This describes where the trials currently stand, and several larger studies are under way; it is a statement about what has been measured, not a conclusion that the effect is absent.
The study · 1
Kirkland 2020, Journal of Internal Medicine · Journal of Internal Medicine, 2020
Muscle And Strength
Dasatinib plus quercetin improved walking speed and strength in aged mice
The dasatinib-and-quercetin combination made old mice faster, stronger and more active, and even a few senescent cells were enough to weaken young mice.
Intermittent dasatinib plus quercetin improved walking speed, endurance and grip strength in naturally aged mice, and transplanting a small number of senescent cells into young mice was enough to cause physical dysfunction that senolytics then reduced. These are mouse measures of function; the same intermittent dosing has not been shown to improve strength or mobility in healthy people.
The study · 1
Xu 2018, Nature Medicine · Nature Medicine, 2018
Respiratory
In 14 pulmonary fibrosis patients, walking distance and gait speed improved while lung function did not
In the first human trial, people with a serious lung-scarring disease could walk a little further and move a little faster after senolytics, though their lung function itself did not change.
In the first human senolytic study, 14 patients with idiopathic pulmonary fibrosis took intermittent dasatinib plus quercetin over three weeks. Measures of physical function improved, including six-minute walk distance and gait speed, while lung function and other clinical measures did not change. It was small, open-label and had no control group, so the improvement could reflect expectation or practice on the tests; it shows feasibility and a signal, not a demonstrated benefit.
The study · 1
Justice 2019, EBioMedicine · EBioMedicine, 2019
How It Works
Senescent cells stay alive by turning up pro-survival networks, the anti-apoptotic switches that block their self-destruct signal, and every senolytic works by interrupting one of those switches. Dasatinib and quercetin are used together, a pairing often called D plus Q, because they cover different cell types: dasatinib is more effective against some senescent cells, quercetin against others. Navitoclax acts differently, blocking the BCL-2 family of survival proteins directly.
Senolytics are dosed in short, intermittent courses. Senescent cells take weeks to build back up, so the drugs are given in brief pulses with long gaps between them. A senolytic needs to be present only briefly to trigger the clearance, which keeps both the exposure and the side effects low. This mechanism sits within the wider biology on the biology of aging, where cellular senescence is one of the recognized hallmarks, and it is closely related to autophagy, the cell recycling process.
How to Read This Field
Two facts about senescent cells are true at once. Through most of the last century these cells were seen as protective: a cell that has stopped dividing cannot become a tumor, so senescence suppresses cancer. That still holds. But once these cells accumulate and stay in aging tissue, they also cause harm through their inflammatory secretions. Clearing them turned senescence from a fixed marker of age into something that can be acted on, and that shift drew the current interest.
Popular use gets ahead of the evidence on dose. Fisetin and quercetin are sold as do-it-yourself senolytics, but the research uses far larger, intermittent doses than a supplement label, and the safety and benefit of those doses in healthy people are not established. Buying the supplement at ordinary amounts is not the intervention that was tested.
For anyone following this field now:
- Watch the trials as they report, and treat the mouse results as a reason for interest, not a protocol.
- Treat strong evidence in mice as evidence about mice; such results have often failed to carry over to people.
- Remember that supplement-label amounts are far smaller than the intermittent research doses.
Go Deeper
- The biology of aging: where cellular senescence sits among the twelve hallmarks of aging, and why the anti-aging molecules as a group are earlier in development than their marketing.
- Autophagy: the cellular recycling process closely related to how the body handles worn-out components, and a target of its own in the aging field.
- Urolithin A: another compound from the longevity conversation that has reached human trials, useful as a comparison for how to read early evidence.
The Chinese Medicine View
Senescent cells were described only in the modern era, so there is no classical Chinese term for them, no channel a senolytic enters, and no traditional preparation. What follows uses the tradition as a lens, and invents no classical words about something the old texts did not see.
Two of the tradition's ideas sit near where senolytics act. The first is the emphasis on clearing what the body no longer needs. Chinese medicine reads health partly as the free movement and turnover of the body's substances, and it treats the buildup of the stale, the stagnant, and what the classics call turbidity as a root of many patterns. A therapy that removes worn-out cells so healthy tissue can renew lines up with that theme at the level of the cell: clearing the old to make room for the new. The second is the Kidney and its store of Jing, the essence, understood as the deep constitutional reserve drawn down across a lifetime, whose decline the classics describe in signs close to what modern medicine calls aging.
The tradition also carries its own caution here. Chinese medicine does not hold that clearing is always good. It draws a careful distinction between when to clear and drain and when to tonify and support, and it warns that draining methods used in someone who is weak or depleted can do harm. A cold, draining approach applied to a deficient person injures the reserve you are trying to protect. Read through that lens, the senolytic idea is neither endorsed nor dismissed. The bridge places it inside a system that has long reasoned about clearing versus nourishing, without lending the drugs any clinical claim the tradition did not make. The evidence for senolytics stands on the trials.
Cautions For This Practice
Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Dasatinib is a prescription cancer drug
Dasatinib is an approved leukemia chemotherapy, and it carries the side effects of one, including fluid around the lungs, lowered blood counts, and bleeding risk. In senolytic research it is used only in monitored clinical trials, in short intermittent courses. It is not something to obtain or self-administer.
Navitoclax lowers platelet counts
Navitoclax blocks a survival protein that platelets also rely on, so it reduces the platelet count and raises bleeding risk. It remains an investigational drug studied under close monitoring.
Senolytic doses of fisetin and quercetin are not established
Fisetin and quercetin are sold as ordinary supplements at nutritional doses. Senolytic research uses far larger intermittent doses whose safety and benefit in people are not established, and taking large supplement doses to copy a trial is not supported by the current evidence.
This is not a do-it-yourself protocol
The senolytic trials are run in monitored clinical settings, with medical screening, defined doses, and follow-up. Assembling a home regimen from supplements and a sourced prescription drug skips every one of those safeguards, and the doses that worked in trials are not the doses on a supplement shelf.
These compounds interact with medications
Quercetin and dasatinib both affect the enzymes and transporters that clear other drugs, so they can change the blood levels of medicines a person already takes. Anyone on prescription drugs would want a pharmacist or clinician to check for interactions.
No safety data in pregnancy or breastfeeding
None of these compounds has safety data at senolytic doses during pregnancy or breastfeeding, so they are best avoided in those periods.
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
Common Questions
What are senolytics?
Senolytics are compounds that aim to clear senescent cells, the worn-out cells that stop dividing but resist dying and build up in tissue with age. Those cells leak inflammatory signals, the senescence-associated secretory phenotype, that irritate the tissue around them. Senolytics work by blocking the survival programs senescent cells depend on, so the cells clear themselves while healthy dividing cells are largely spared. The best-known agents are dasatinib combined with quercetin, the flavonoid fisetin, and the investigational drug navitoclax.
Do senolytics work in humans?
The human evidence is early and small. Two published pilots, one in idiopathic pulmonary fibrosis and one in diabetic kidney disease, showed that senolytics can reduce senescent-cell markers and, in the lung study, improve physical function such as walking distance. Both were tiny, neither had a control group, and neither measured survival or disease outcomes. So the drugs do measurably clear senescent cells and can shift a function test in people, and no study has yet shown that they make anyone live longer or healthier. Larger trials are under way.
Are fisetin and quercetin supplements senolytics?
Fisetin and quercetin are flavonoids that acted as senolytics in laboratory and animal studies, and they are sold widely as inexpensive supplements. The catch is dose. The senolytic research uses far larger, intermittent doses than the nutritional amounts on a supplement label, and the safety and benefit of those research doses in healthy people are not established. Buying the supplement at ordinary doses is not the same as the intervention that was tested.
Is it safe to take dasatinib for aging?
Dasatinib is a serious prescription chemotherapy drug approved for leukemia, with side effects that include fluid around the lungs, lowered blood counts and bleeding risk. In senolytic research it is used only in monitored clinical trials, in short intermittent courses, in patients who are watched closely. It is not a supplement and is not something to source or take on your own for aging.
Will senolytics extend human lifespan?
That has not been shown. Clearing senescent cells extended lifespan in mice, which is a strong animal result, but mouse lifespan findings have often failed to carry over to people. In humans, senolytics have so far moved cellular markers and small physical-function tests over short periods, which is not the same as adding years or preventing disease. The accurate reading is a promising mechanism with strong mouse data whose human longevity benefit is not established, and one to follow as the larger trials report.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 10 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.